New Delhi, Feb. 24 -- Drugs Controller General of India (DCGI) has sought active post-market surveillance data from the drugmakers of two fixed-dose combination (FDC) medicines-Imipramine Hydrochloride IP + Diazepam IP tablets used to ease co-morbid anxiety conditions, and Chlorphenamine Maleate IP + Ammonia Chloride IP + Sodium Citrate IP syrup used to relieve cough and respiratory distress.

The top drug regulator has given three months' time to the companies to submit the report, failing which appropriate regulatory action would be taken. The drugs were given manufacture and sale licence by state/Union territory (UT) governments without due approval from the Central Licensing Authority.

Post-market surveillance data is information abo...